Cordis today announced that it has appointed Christopher Scully as chief financial officer.
Scully will be responsible for leading the interventional cardiovascular technology company’s financial and IT functions to accelerate Cordis’s growth.
Prior to joining the company, Scully was executive VP and CFO for PPD. He played a role in the company’s IPO and its eventual sale to Thermo Fisher Scientific for an enterprise value greater than $20 billion.
“At Cordis, we are building a platform for medical device innovation that is possible only by tapping into the experience and insight of leaders like Chris Scully,” Cordis CEO Shar Matin said in a news release. “His record of achievement reflects his acumen and proficiency in developing long-term growth strategies that produce exceptional results.”
Scully also held numerous leadership roles at Pfizer, including chief commercial officer for its essential health business, regional president of established products in Europe and VP of finance and CFO for its established products business.
“Cordis is a company with a rich history in cardiovascular technology, and I’m excited to be part of its dynamic path forward,” said Scully. “Working with colleagues and physicians around the world, I anticipate we will bring important and innovative solutions that will change lives and improve patient care.”